Status:
COMPLETED
A Study In Patients With Non-Small Cell Lung Cancer To Test If Erlotinib Plus SU011248 Is Better Than Erlotinib Alone
Lead Sponsor:
Pfizer
Conditions:
Carcinoma, Non-Small Cell Lung
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This study will test whether treatment with erlotinib plus SU011248 is better than erlotinib alone in patients with advanced/metastatic lung cancer who have received previous treatment with a platinum...
Eligibility Criteria
Inclusion
- Patients with locally advanced/metastatic non-small cell lung cancer
- Prior treatment with no more than 2 chemotherapy regimens including a platinum-based regimen
Exclusion
- Prior treatment with any receptor tyrosine kinase inhibitors, VEGF inhibitor (with the exception of bevacizumab) or other angiogenesis inhibitors
- History of or known brain metastases
Key Trial Info
Start Date :
July 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2012
Estimated Enrollment :
960 Patients enrolled
Trial Details
Trial ID
NCT00457392
Start Date
July 1 2007
End Date
December 1 2012
Last Update
October 29 2013
Active Locations (204)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Florence, Alabama, United States, 35630
2
Pfizer Investigational Site
Muscle Shoals, Alabama, United States, 35661
3
Pfizer Investigational Site
Scottsdale, Arizona, United States, 85258
4
Pfizer Investigational Site
Hot Springs, Arkansas, United States, 71913